Emerging Strategies in the Treatment of ALL

For High-Definition, Click

Several new therapies have recently become available or are under exploration for the treatment of patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL). In 2012 the FDA granted accelerated approval for vincristine sulfate liposome injection (Marqibo) for the treatment of adult patients with Ph-negative ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

In addition to this therapy, the many T cells therapies coming down the line are extremely exciting, panelists believe. Moreover, the cytokine release syndrome of the CAR therapies or the infusion-related status epilepticus of blinatumomab appear manageable, even outside of academic settings. Additionally, the technology utilized to measure response has increased greatly with the introduction of minimal residual disease tests.

Related Videos
Eunice Wang, MD
Expert on DLBCL
Tycel Phillips, MD
Expert on ALL
Yiming Wu, PhD
Michael Andreeff, MD, PhD
Brian C. Ball, MD
Mitchell E. Horwitz, MD
Bradley W. Christensen, MD
Jorge E. Cortes, MD
Related Content